In this webinar, in collaboration with IntelliCyt, Robert Ford, Ph.D. from Avacta Life Sciences provides an overview of novel anti-idiotpyic Affimer® reagents and their importance in the bioanalysis of therapeutic antibody drug candidates. He demonstrates how Affimer reagents are identified, incorporating cross-reactivity profiling against similar antibody drug candidates into the primary screening phase of the discovery process.
Access the free webinar recording to find out more.
*By registering your email you agree to receive further updates from Avacta Life Sciences about our products and services which are specific to your areas of interest.